Author

Jen Godden

Observed names: J Godden, J L Godden, J.L Godden

Institution: Tempus Labs (United States)

Observed institutions: Tempus Labs (United States), University of Glasgow

OpenAlex ID: A5113698084

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

2005 · H G Jørgensen, E K Allan, et al. · Leukemia · 70

The response of breast cancer cells to steroid and peptide growth factors.

1992 · J Godden, R Leake, et al. · PubMed · 28

Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis—The role of platelet-derived growth factor

1999 · J.L Godden, M Edward, et al. · European Journal of Cancer · 17

Bioassay of transforming growth factor-beta activity in acidic protein extracts from primary breast cancer specimens.

1993 · J Godden, C Porteous, et al. · PubMed · 5

Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in KRAS-STK11 NSCLC.

2025 · Joshua Pothen, Jen Godden, et al. · Journal of Clinical Oncology

Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst KRAS mutational variants in non-small cell lung cancer

2025 · Frank D. Weinberg, Jen Godden, et al. · Cancer Research

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.

2023 · Rachel Minne, Natalie Luo, et al. · Journal of Clinical Oncology

Effect of retinoic acid on melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis

1997 · M Edward, J L Godden, et al. · Melanoma Research

Works count: 8

Citation count: 120

H-index: 4

I10-index: 3